Page 322 - ATP-P 11th Ed

facial paralysis, hypertonia, nervousness, neuropathy, peripheral neuritis, somno-
lence, thinking abnormal, tremor, and vertigo
• Respiratory system
° Asthma, cough, increased dyspnea, lung edema, pharyngitis, rhinitis, and sinusitis
• Skin and appendages
° Acne, alopecia, dry skin, eczema, exfoliative dermatitis, furunculosis, maculopapular
rash, nail disorder, pruritis, seborrhea, skin benign neoplasm, skin discoloration, skin
striae, skin ulcer, and sweating
• Special senses
° Abnormal vision, eye disorder, otitis media, taste loss, taste perversion, and tinnitus
• Urogenital system
° Abnormal ejaculation, amenorrhea, breast enlargement, gynecomastia, impotence,
kidney calculus, nephritis, and urine abnormality
Other notes:
®
• Store Kaletra soft gelatin capsules at 36° F–46° F (2° C–8° C) until dispensed. Avoid
SECTION 3 TMEP use: HIV Post Exposure Prophylaxis Protocol
exposure to excessive heat. For patient use, refrigerated Kaletra capsules remain stable
until the expiration date printed on the label. If stored at room temperature up to 77° F
(25° C), capsules should be used within 2 months.
Ketalar – See Ketamine
®
Ketamine (Ketalar )
®
GROUNDING medication for personnel on flight status
Description: Rapid acting general sedative and analgesic
Indications: Anesthetic agent for procedures
Adult dose: 20mg IV/IO over 1 minute, followed by 20mg increments every 30–60 seconds
until nystagmus occurs or a maximum total dose of 100mg
Do not administer faster as this may result in respiratory depression.
K9 Dose: 5mg/kg IV (use with 0.3mg/kg midazolam)
Contraindications:
• Hypersensitivity to ketamine
Pregnancy Category B
Adverse effects:
• Hypertension
• Respiratory depression
• Emergence reactions (delirium, hallucinations, confusion)
• Increased intracranial pressure
• Increased intraocular pressure
• Hypersalivation
312 SECTION 3 RECOMMENDED DRUG LIST (RDL)